Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan D Cassaday

Showing results (11-20 of 112) with videos related to

Pageof 12
Sort By:
Blood and Lymphatic Cancer : Targets and Therapy|June 7, 2022
Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in TherapyKrishna R Juluri, Chloe Siu, Ryan D Cassaday
Hematology. American Society of Hematology. Education Program|December 5, 2025
Peri-transplant conundrums: optimizing maintenance therapy using MRD-directed approachesSuravi Raychaudhuri, Ryan D Cassaday, Mary-Elizabeth M Percival
Clinical Lymphoma, Myeloma & Leukemia|June 11, 2011
Regression of Hodgkin lymphoma after discontinuation of a tumor necrosis factor inhibitor for Crohn's disease: a case report and review of the literatureRyan D Cassaday, Jeffrey T Malik, Julie E Chang
Genesis (New York, N.Y. : 2000)|April 12, 2002
Cell-specific transgene expression from a widely transcribed promoter using Cre/lox in micePaul J Grippo, Patrick S Nowlin, Ryan D Cassaday, et al.
Case Reports in Hematology|March 22, 2017
Spontaneous Remission of an Untreated, MYC and BCL2 Coexpressing, High-Grade B-Cell Lymphoma: A Case Report and Literature ReviewD Alan Potts, Jonathan R Fromm, Ajay K Gopal, et al.
American Journal of Hematology|February 23, 2017
Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasmMatthew L Ulrickson, Akshjot Puri, Sarah Lindstrom, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2015
A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphomaRyan D Cassaday, Andre Goy, Suresh Advani, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 13, 2024
Retrospective review of the toxicities and change in dosing patterns for pegaspargase in patients with acute lymphoblastic leukemia/lymphoma and T-cell lymphomaGrace Baek, Miryoung Kim, Madison Lee, et al.
Expert Review of Hematology|January 8, 2025
Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature reviewDavid I Marks, Ryan D Cassaday, Josep-Maria Ribera, et al.
Expert Review of Hematology|May 21, 2025
Identifying people with acute lymphoblastic leukemia who are most suitable for treatment with inotuzumab ozogamicin: a plain language summaryDavid I Marks, Ryan D Cassaday, Josep-Maria Ribera, et al.
Pageof 12

Showing results (11-20 of 112) with videos related to

Sort By:
Pageof 12
Blood and Lymphatic Cancer : Targets and Therapy|June 7, 2022
Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in TherapyKrishna R Juluri, Chloe Siu, Ryan D Cassaday
Hematology. American Society of Hematology. Education Program|December 5, 2025
Peri-transplant conundrums: optimizing maintenance therapy using MRD-directed approachesSuravi Raychaudhuri, Ryan D Cassaday, Mary-Elizabeth M Percival
Clinical Lymphoma, Myeloma & Leukemia|June 11, 2011
Regression of Hodgkin lymphoma after discontinuation of a tumor necrosis factor inhibitor for Crohn's disease: a case report and review of the literatureRyan D Cassaday, Jeffrey T Malik, Julie E Chang
Genesis (New York, N.Y. : 2000)|April 12, 2002
Cell-specific transgene expression from a widely transcribed promoter using Cre/lox in micePaul J Grippo, Patrick S Nowlin, Ryan D Cassaday, et al.
Case Reports in Hematology|March 22, 2017
Spontaneous Remission of an Untreated, MYC and BCL2 Coexpressing, High-Grade B-Cell Lymphoma: A Case Report and Literature ReviewD Alan Potts, Jonathan R Fromm, Ajay K Gopal, et al.
American Journal of Hematology|February 23, 2017
Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasmMatthew L Ulrickson, Akshjot Puri, Sarah Lindstrom, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2015
A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphomaRyan D Cassaday, Andre Goy, Suresh Advani, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 13, 2024
Retrospective review of the toxicities and change in dosing patterns for pegaspargase in patients with acute lymphoblastic leukemia/lymphoma and T-cell lymphomaGrace Baek, Miryoung Kim, Madison Lee, et al.
Expert Review of Hematology|January 8, 2025
Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature reviewDavid I Marks, Ryan D Cassaday, Josep-Maria Ribera, et al.
Expert Review of Hematology|May 21, 2025
Identifying people with acute lymphoblastic leukemia who are most suitable for treatment with inotuzumab ozogamicin: a plain language summaryDavid I Marks, Ryan D Cassaday, Josep-Maria Ribera, et al.
Pageof 12